Abstract
Background
We analyzed the racial differences in physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific worry among men with clinically localized prostate cancer.
Methods
In this prospective cohort study, we recruited 121 Caucasian and 77 African American men with newly diagnosed prostate cancer. Participants completed the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument at baseline and at 3, 6, 12 and 24 months follow-up. To determine the between and within group differences on all functional measures (physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific concerns), we used repeated measures ANOVA.
Results
Except for education, income and hospital type, the two racial groups had comparable socio-demographic and clinical attributes. At 3 months post-treatment, both groups experienced a decline in physical well-being and increase in prostate cancer specific concerns. Baseline values of these measures were not recovered by 24-month follow-up. In particular, lack of energy was the most prominent contributor to declining physical well-being. The ability to have and maintain an erection was the most severe prostate cancer specific concern. Lack of energy and concern regarding erection ability varied between the two groups over the follow-up period.
Conclusions
Our findings provide an insight into not only the overall racial variation in physical health and prostate cancer specific concern, but also the temporal differences in these measures that can occur over a 24-month follow-up. This has important implications for effective management of localized prostate cancer patients from different racial groups and merits further research.
Similar content being viewed by others
References
Jemal A, Siegel R, Xu J, Ward E. Cancer facts and figures. CA A Cancer J Clin. 2010;60:1–25.
Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of PCa. J Gen Intern Med. 2004;19(2):146–55.
Lubeck DP, Kim H, Grossfeld GD, Ray P, Penson DF, Flanders SC, et al. Health related quality of life differences between black and white men with PCa: Data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2001;166:2281–5.
Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of Local/Regional Carcinoma of the prostate. J Clin Oncol. 1995;13(1):93–100.
Young CD, Roach M. Race and prostate cancer: What do we know? Prostate Journal. 2000;2(1):33–41.
Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504–7.
Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB. Ethnic variation in return to baseline values of patient reported outcomes in older prostate cancer patients. Cancer. 2007;109(11):2229–38.
Johnson TK, Gilliland FD, Hoffman Rm, Deapen D, Penson DF, Stanford JL, et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol. 2004;22(20):4193–201.
Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437–42.
McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer Screening and Treatment, 1990–2000. J Natl Cancer Inst Monogr. 2004;33:78–101.
Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol. 2004;172:S13–7.
Litwin MS, Saigal CS (editors). Urologic diseases in American. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2007; NIH Publication No. 07-5512.
Denberg TD, Beaty BL, Kim FJ, Steiner JF. Marriage and ethnicity predict treatment in localized carcinoma. Cancer. 2005;103:1819–25.
Litwin MS, McGuigan KA, Shpall AI, Dhanani N. Recovery of health related quality of life in the year after radical prostatectomy: early experience. J Urol. 1999;161:515–9.
Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol. 2001;166:587–92.
Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001;92:1451–9.
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy—prostate instrument. Urology. 1997;50:920–8.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Disease. 1987;40:373–83.
Barnett PG. Review of methods to determine VA-health care costs. Med Care. 1999;37(4):AS9–17.
Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56:968–76.
Oakes M. Statistical Inference. Chestnut Hill, Massachusetts: Epidemiological Resources; 1990.
Statistical Analysis System (SAS), Version 9.2 SAS Institute, Cary, NC.
Stone PC, Murphy RF, Matar HE, Almerie MQ. Measuring the individual quality of life of patients with prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:390–6.
Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the prostate cancer outcomes study. Am J Med. 2006;119:418–25.
Joseph KJ, Alvi R, Skarsgard D, Tonita J, Pervez N, Small C, et al. Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, 1 year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDBRT). Radiat Oncol. 2008;20:1–5.
Ukoli FA, Lynch BS, Adams-Campbell LL. The effect of radical prostatectomy on patient quality of life in African Americans. Radical prostatectomy and quality of life among African American. Ethn Dis. 2006;16:988–93.
Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.
Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman BG, et al. Ethnic variations in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004;3(1):31–7.
Soni MK, Cella D. Quality of Life and Symptom measures in oncology: an overview. Am J Manage Care. 2002;8:S560–73.
Lee WB, McQuellon RP, Case LD, DeGuzman AF, McCullough Dl. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 162:403–6.
Ward-Smith P, Mehl J. Quality of life before and after prostatectomy as treatment for localized cancer. Urol Nurs. 2007;27(6):542–7.
Acknowledgements
Supported by the DOD prostate cancer Research Program W81XWH-04-1-0257.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chhatre, S., Wein, A.J., Malkowicz, S.B. et al. Racial differences in well-being and cancer concerns in prostate cancer patients. J Cancer Surviv 5, 182–190 (2011). https://doi.org/10.1007/s11764-011-0170-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-011-0170-1